Analytical Data
-
Gene name
NXNL2
- Application
-
Alternative Names
Rod-derived cone viability factor 2 ;RdCVF2
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5VZ03
-
Expression Region
1-135aa
-
Molecular Weight
30.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NXNL2, a member of the N-terminally extended NRL family, has garnered significant attention in recent years due to its crucial role in retinal health and function. It is primarily expressed in retinal photoreceptors, where it is believed to play a vital role in phototransduction and the protection of photoreceptor cells from stress-induced apoptosis. Research has indicated that mutations in the NXNL2 gene can lead to various forms of inherited retinal dystrophies, which often present with severe visual impairment or blindness. Given its importance in retinal biology, scientists have focused on the characterization of NXNL2 as a recombinant protein to understand its molecular mechanisms, interactions, and potential therapeutic applications. By producing NXNL2 in a recombinant form, researchers aim to elucidate its structure-function relationship, investigate its role in photoreceptor survival, and explore its potential as a target for gene therapy approaches. Furthermore, the study of NXNL2 may also provide insights into the broader pathways involved in retinal degeneration, thereby enhancing our understanding of disease mechanisms and aiding in the development of innovative treatments for retinal diseases. As such, NXNL2 is not only a critical player in photoreceptor biology but also a promising candidate for future therapeutic strategies to combat retinal disorders.
